Sell EnteroMedics And Step To The Sidelines
Scientist on Stocks - at Seeking Alpha - Tue Dec 30, 11:25AM CST
OREX: 6.06 (+0.12), ETRM: 1.42 (+0.04), VVUS: 2.88 (+0.10), ARNA: 3.47 (+0.07)
Can High Priced Novo Nordisk Anti-Obesity Injection Make It?
Spencer Osborne - at Seeking Alpha - Mon Dec 29, 12:30PM CST
OREX: 6.06 (+0.12), NVO: 42.32 (-0.35), VVUS: 2.88 (+0.10), ARNA: 3.47 (+0.07)
The Obesity Treatment Market Could Finally Achieve Some Of Its Potential In 2015
Kanak Kanti De - at Seeking Alpha - Mon Dec 29, 12:24PM CST
OREX: 6.06 (+0.12), NVO: 42.32 (-0.35), VVUS: 2.88 (+0.10), ARNA: 3.47 (+0.07)
Arena - Belviq Advertsing Closes Out Year With Big Push
Spencer Osborne - at Seeking Alpha - Mon Dec 29, 12:13PM CST
OREX: 6.06 (+0.12), VVUS: 2.88 (+0.10), ARNA: 3.47 (+0.07)
Is Vivus Headed Towards An Unfortunate Ending?
Alexander Maxwell - at Seeking Alpha - Sat Dec 27, 7:27AM CST
OREX: 6.06 (+0.12), NVO: 42.32 (-0.35), VVUS: 2.88 (+0.10), ARNA: 3.47 (+0.07)
The Newest FDA-Approved Obesity Drug Is Also the Oldest
Brian Orelli, The Motley Fool - Motley Fool - Sat Dec 27, 7:04AM CST
Novo Nordisk on Tuesday gained Food and Drug Administration approval for its obesity drug Saxenda. While that is not the feat it would have been a few years ago, Novo Nordisk can boast that its obesity drug was approved on its first try, unlike ...
OREX: 6.06 (+0.12), NVO: 42.32 (-0.35), AZN: 70.38 (-0.31), VVUS: 2.88 (+0.10), LLY: 68.99 (-0.65), GSK: 42.74 (-0.05), ARNA: 3.47 (+0.07)
3 Stocks Poised for Eye-Popping Gains in 2015
George Budwell, The Motley Fool - Motley Fool - Sat Dec 27, 6:27AM CST
Source: Flicker via 401kcalculator.org The stock market has been on fire since the start of 2012. Biotech companies, though, have posted particularly impressive gains, markedly outperforming the broader markets during this time period. The ...
OREX: 6.06 (+0.12), GILD: 94.26 (-1.02), VVUS: 2.88 (+0.10), IBB: 303.35 (-1.27), ABBV: 65.44 (-0.86), PRTA: 20.76 (+0.07), ARNA: 3.47 (+0.07)
4 Potential Blockbuster Drugs The FDA Just Approved
at Investor's Business Daily - Fri Dec 26, 11:35AM CST
While the approval of AbbVie's (ABBV) hepatitis C regimen Viekira Pak hogged most of the headlines, over the past week the FDA has approved a whole passel of medicines that could be blockbusters for their makers. Here's a short list of some of the...
OREX: 6.06 (+0.12), MYGN: 34.06 (-0.77), NVO: 42.32 (-0.35), CBST: 100.65 (-0.05), AZN: 70.38 (-0.31), MRK: 56.79 (-0.86), VVUS: 2.88 (+0.10), ABBV: 65.44 (-0.86), BMY: 59.03 (-0.36), ARNA: 3.47 (+0.07)
First Week Of February 2015 Options Trading For Orexigen Therapeutics
at The Street - Fri Dec 26, 10:46AM CST
Investors in Orexigen Therapeutics, Inc. saw new options become available this week, for the February 2015 expiration.
OREX: 6.06 (+0.12)
Shares of OREX Up 42.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Dec 26, 9:24AM CST
SmarTrend identified an Uptrend for Orexigen Therapeutics (NASDAQ:OREX) on October 17th, 2014 at $4.16. In approximately 2 months, Orexigen Therapeutics has returned 42.07% as of today's recent price of $5.91.
OREX: 6.06 (+0.12)
4 Biotech Stocks that Doubled in 2014 - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Dec 26, 8:00AM CST
Promising pipeline candidates, progress on the regulatory front and interesting research platforms helped these 4 biotech stocks stand out in 2014.
ENDP: 72.12 (-0.70), BMRN: 90.40 (+0.07), AMGN: 159.29 (-1.34), MNKD: 5.22 (-0.13), CELG: 111.86 (-1.68), MDVN: 99.61 (+0.72), JNJ: 104.57 (-0.79), OREX: 6.06 (+0.12), ESRX: 84.67 (-1.08), CBST: 100.65 (-0.05), GILD: 94.26 (-1.02), AUXL: 34.38 (-0.26)
Novo Nordisk's Saxenda Gets FDA Nod, Launch in 1H15 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:20PM CST
Novo Nordisk's (NVO) Saxenda received FDA approval as the first once-daily human glucagon-like peptide-1 analogue for chronic weight management.
OREX: 6.06 (+0.12), NVO: 42.32 (-0.35), ARNA: 3.47 (+0.07)
Novo Nordisk Enters Anti-Obesity Space With New FDA Approval
Spencer Osborne - at Seeking Alpha - Wed Dec 24, 6:46AM CST
ZFGN: 30.84 (+0.04), OREX: 6.06 (+0.12), NVO: 42.32 (-0.35), VVUS: 2.88 (+0.10), ARNA: 3.47 (+0.07)
FDA clears Novo Nordisk's weight loss drug Saxenda
AP - Tue Dec 23, 3:49PM CST
NEW YORK (AP) — The Food and Drug Administration has approved a Novo Nordisk diabetes drug as a treatment for obesity. It's the first injectable drug approved for weight loss.
OREX: 6.06 (+0.12), VVUS: 2.88 (+0.10), ARNA: 3.47 (+0.07)
FDA clears Novo weight management drug
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 3:05PM CST
OREX: 6.06 (+0.12), NVO: 42.32 (-0.35), VVUS: 2.88 (+0.10), ARNA: 3.47 (+0.07)
Orexigen's Obesity Drug Mysimba Gets CHMP Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 5:10PM CST
The CHMP gave a positive opinion on the approval of Orexigen's (OREX) weight loss drug, Mysimba.
BIIB: 339.45 (-2.74), OREX: 6.06 (+0.12), AMGN: 159.29 (-1.34)
Contrave Prescriptions Still Rising In A Down Week
Clinically Sound Investor - at Seeking Alpha - Mon Dec 22, 2:47PM CST
OREX: 6.06 (+0.12), VVUS: 2.88 (+0.10), ARNA: 3.47 (+0.07)
Orexigen - Contrave Script Numbers Remain Impressive
Spencer Osborne - at Seeking Alpha - Mon Dec 22, 2:31PM CST
OREX: 6.06 (+0.12), VVUS: 2.88 (+0.10), ARNA: 3.47 (+0.07)
Belviq Scripts Dip - Lack Of T.V. Ads Will Impact Next Numbers
Spencer Osborne - at Seeking Alpha - Mon Dec 22, 2:27PM CST
OREX: 6.06 (+0.12), VVUS: 2.88 (+0.10), ARNA: 3.47 (+0.07)